EN
CN EN

Grand Shuyang "Sunshine Sea" Golden Scholar Fund 2026 Charity Event Successfully Concluded

2026-09-01 16:37

Recently, ten plasmapheresis centers under Grand Shuyang Life Sciences (Chengdu) Co., Ltd. jointly launched the 2026 "Sunshine Sea" Gold Scholar Fund educational assistance campaign. The campaign covered Sichuan and Guangxi provinces, reaching over 400 donors' families, with financial support of nearly RMB 600,000.

eb4909839ee24dc2a91603ea13c5b7ab.png

About the "Sunshine Sea" Charity Fund

The "Sunshine Sea" Charity Fund is a public welfare platform independently established and continuously operated by Grand Shuyang. It is dedicated to providing donors and their families with long-term care based on their actual needs, such as health security, children's education, and hardship assistance. To date, the "Sunshine Sea" Charity Fund has reached 86,000 individuals, invested RMB 3.9 million, and gradually become a charity system covering medical assistance, educational assistance, and poverty relief.

As an educational assistance campaign under the "Sunshine Sea" Charity Fund, the Golden Scholar Fund has been established to support the educational promotion of donors' children. Each year, it provides financial assistance to eligible families to help ease their financial burden associated with educational promotion. Through the continued implementation of the Golden Scholar Fund and other charity events, Grand Shuyang has built a routine care system for donors' families, translating corporate social responsibility into concrete, long-term supportive actions.

Looking ahead, Grand Shuyang remains committed to integrating social responsibility into every aspect of corporate development. While ensuring the safe supply of blood products and safeguarding public health, we will also actively address the needs of donors, patients, communities and other stakeholders. In doing so, we seek to create synergies between corporate and social value, and to repay society with enduring, stable, and sustainable action.